Our Time is Now.  Get Involved.
Since the End of the Prohibition on Recreational Use of Cannabis in California

Investor MYDX Report

Market Growth

Of the US population live in regions where cannabis is legal

Top 3 Ailments and Side Effects
40 million

Americans say they smoke marijuana

Next Generation of Drug Discovery

Unique MyDx consumer generated data points are being used for cannabis- related drug discovery

The MyDx Investment Opportunity
114X, 8.75X

Median Pharma Peer Market Cap/ Sales vs. MyDx multiple of 8.75x

Sign Up for Live Demo and Stay Updated

North American Cannabis Market

The legal cannabis industry in North American is expected to accelerate at an unprecedented growth rate of ~20% over the next 5 years, becoming a $20+bn industry in 20211.

However, the opportunity could be even greater according to estimates:

$2,400 / yr

~55% of users spend $200 or more per month3

~40m Adults

1 in 8 U.S. Adults say they smoke marijuana4

~$100bn / yr

Industry Potential


Of the U.S. population live in a state where a form of cannabis is legal2

Despite only 28 States and Washington D.C. having some form of legalization. This means those waiting on the sidelines to invest until cannabis has been legalized nationally, will potentially miss out on early opportunities that have the potential for out-sized returns, given the industry is "nationalized" population-wise. Early movers have invested $1.2bn in 2016 and over $700mm so far in 20175.

  • (1) ArcView Industry Research, 2017
  • (2) New Frontier Data, 2017
  • (3) Cannabis Consumers Coalition Report, 2017
  • (4) Gallup Poll, 2016
  • (5) According to Veridian Capital Advisors
Today, Over 40 million Americans Use Cannabis to Achieve a Desired Effect

Top 3 Ailments Patients are Looking to Relieve:

1 Pain
2 Anxiety
3 Depression
I need something that's going to help with my back pain, but won't put me to sleep. - Vannessa
Thanks for connectiog. Use the MyDx One App to find what you're looking for. Our Recommendation Engine has input from People all over the world solving that very same problem! - Mobile

Top 3 Feelings Adults are Looking to Achieve:

1 Energetic
2 Focused
3 Sleepy

The Cannabis Industry’s first hand-held cannabis tester and analyzer. Equipped to accommodate multiple sensors that test for toxins and impurities in the air you breathe, the foods you eat, and the water you drink.

The cannabis industry’s first Smart Vaporizer Pen Integrated with Bluetooth technology that will allow for mobile-app control, dose tracking and restrictions, child safety controls, and usage statistics.

MyDx360 is a Software As A Service (SAAS)-based community engagement platform designed to help entrepreneurs develop, launch and track the effects and feedback of formulated products on consumers.

MyDx will sell/ license cannabis formulations designed to alleviate various ailments. Chemical formulations will be confirmed by formal clinical trials.

MyDx Smart Devices Help You:

Get Community Input and Recommendations

Based on what you want relieved or how you want to feel

Test Your Sample

To confirm purchase and know its effect based on its chemical profile and community input

Figure Out How
Much to Use

To find the relief you need when you need it by monitoring your consumption habits

Over 55k

Community inputs are helping us to discover new
drugs to alleviate pain, anxiety, sleep and more

The Process of MyDx Innovation
We deploy and sell MyDx products and services to empower consumers to take charge of their cannabis prescription and consumption habits.
Our devices actively and passively collect data that tie exact strain chemical formulations and dosages to their physiological effects. We are then able to analyze and generate meaningful insights from our data that can be used for a wide range of activities.
Since we know what and how people are using cannabis products to alleviate specific ailments, we can then create our own formulas to address those s`ame and/or different ailments.
Once we confirm our findings via formal clinical trials, we can use, sell or license those formulations to develop bio-pharmaceuticals and other consumer products.

Delivery Mechanisms:

Concentrates | Edibles | Drinks | Pills | Body Creams | Pen | Tinctures

MyDx will commence clinical trials to discover and identify green Active Pharmaceuticals (gAPI's)

Median Pharmaceutical Peer
Equity Value / Sales Multiple:


MyDx Equity Value /
Sales Multiple:


Pharma Peers:

MyDx also compares favourably to Syqe Medical


Private Company

Received $20mm investment led by Phillip Morris, Int'l


Syqe Medical is an Israeli start-up that developed a metered-dose vaporiser of raw plants for medical use.

The platform is further comprised of proprietary raw drug Structural- Modification methods, uniquely identified
preloaded cartridges
and a linked clinical
database serving
physicians, researchers
and healthcare entities.

Proprietary Process

The Syqe



MyDx is a science and technology company that developed a dosage-controlled vaporiser that allows consumers to discover what works best for them based on their own physiologies. With a proprietary flow meter, users can determine how many “puffs” it takes to achieve the effect they’re looking for with any lab-tested concentrate.

Linked to the MyDx360 platform, consisting of the MyDx ONE App and cloud database, serving physicians, administrators and the MyDx Community.

Proprietary Process

MyDx Eco
smart Pen

Pharmaceutical Competitors
($mm) Description   Market Cap 2016A Sales Multiple
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from it's cannabinoid product platform in a range of disease areas. $ 2,900 $ 13 223.1x
Aphria Inc., is a Canada-based company, which is engaged in producing and selling medical marijuana through retail sales and whoesale channels. $ 1,080 $ 20 54.0x
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entites designed to alleviate pain and pruritus by focusing on kappa opioid receptors. $ 430 $ - N/A
AXIM Biotechnologies, Inc. is a biotechnology company engaged in developing the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinds-based products. $ 424 $ - N/A
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. $ 348 $ 2 174.0x
CanniMed Therapeutics Inc is a Canada-based plant biopharmaceutical company. It is Specicalized in the rpduction of pharmaceutical-grade cannabis. Through it's subsbidiary CanniMed Ltd. the comapany offers medical cannabis oils, dried medical cannabis, vaporizers, vaporizer, vaporizer parts and accessories. $ 264 $ 10 26.4x
Aynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. $ 133 $ - N/A
MyDx is a science and technology company that develops smart devices that allows consumers to discover what works best for them based on their own physiologies. $ 7 - 8.75x

"Unlike most pharmaceutical companies, we’re not starting with the compounds and seeing where it takes us. Instead, we're using crowd-sourced, pre-clinical data to let us know what and how much people are using to alleviate specific ailments and using that information to drive the basis upon which our sets of clinical trials will commence."

- Daniel Yazbeck, CEO of MyDx

Our Team

Daniel Yazbeck

Chairman | CEO | Founder

Experienced Executive
Over 15 years of product research, development and commercialization experience Scientist for Pfizer Pharmaceuticals, specializing in Chemical R&D technologies Strategic Product & Market Developer for Panasonic, engineering new products with strategic partners in the consumer electronics & healthcare industries

Seasoned asset-backed investor at Yazbeck Investments
M.S. from McGill University

Robert Vigil

VP Software Engineering

Experienced software manager and engineer who created the MyDx App Responsible for building and managing the foundational software to support sensory testing devices Over 25 years of software development and management experience with his own online companies and with fortune 500 companies

He has been a lead developer and software manager in the U.S. NAVY, SAIC, Jacobs Laboratories,
Boeing and Unidev

Nicholas Hadler

VP Operations | Co-Founder

Responsible for optimizing the company's sales systems and affiliate network, as well as better managing customer service processes and procedures Seasoned social media expert on all platforms – integral in establishing MyDx’s social media presence

B.A. Economics from UCSB

Joshua Londono

Director R&D

Specialty in data analytics, hardware and software systems
Served in the US Marine Corps in their Legal Affairs Department
Has been with MyDx since 2014 supporting product development

Press / News

Company Name: MyDx Inc.
Ticker: MYDX:US
Website: www.mydxlife.com
Address: MyDx, Inc.
6335 Ferris Square, Suite B
San Diego, CA 92121

Don’t miss out.
Your time is now.
Investor MYDX Report

Since the End of the Prohibition on Recreational Use of Cannabis in California
Sign Up for Live Demo and Stay Updated

Disclaimer: All statements and expressions are the sole opinion of the Company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.

Privacy Policy   Contact Us